$BIOCON– Positive Development

$BIOCON Biocon's long-standing partner Duopharma Biotech has secured insulin supply contracts worth over RM225 million (450 crore) from Malaysia's Ministry of Health. Under these agreements, Biocon's Malaysian subsidiary will supply human insulin, insulin glargine, and insulin as part for nationwide distribution over the next 2–3 years. The contracts strengthen Biocon's presence in the international insulin market, provide revenue visibility, and reinforce its position as a leading global provider of affordable diabetes therapies. A positive development supporting Biocon's growing global biopharmaceutical franchise and long-term insulin business growth. 📈